Skip to content

Efficacy and Safety of Tranexamic Acid in Single segmental lumbar disc

Efficacy and Safety of Tranexamic Acid in Single segmental lumbar disc

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006414
Enrollment
Unknown
Registered
2015-05-18
Start date
2015-05-18
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lumbar disc herniation

Interventions

Experimental:Tranexamic Acid

Sponsors

Honghui Hospital Affiliated to Xi'an Jiaotong University/xi'anHonghui Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The isolated segment need surgical treatment of lumbar disc prolapse patients (L 4-5 or L5 - s1); 2. 20-65 years old; 3. The preoperative blood routine, coagulation series suggest not seen obvious abnormity, not merge blood disease; 4. no varicose veins of lower limb, thrombotic diseases such as atrial fibrillation; 5. No oral method waring affect blood clotting drugs previous history; 6. and no cerebral infarction, previous myocardial infarction, diabetes and other medical diseases.

Exclusion criteria

Exclusion criteria: 1. fracture-dislocation above L4-5; 2. With fatal injury can't tolerate surgery such as severe craniocerebral injury/Abdominal/chest internal bleeding; 3. With hemopathy or high risk for thrombus; 4. no medical illnesses that would preclude an operative intervention; 5. no ongoing cancer, infection, bleeding disorder, or skin disease.

Design outcomes

Primary

MeasureTime frame
Intraoperative bleeding;postoperative drainage;recessive loss of blood;Thrombosis of lower limb;

Contacts

Public Contactwangwentao
731624568@qq.com+86 13572571402

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026